OLAS Pharmaceuticals

OLAS Pharmaceuticals is a biotechnology company focused on developing novel small molecule therapeutics for neurodegenerative diseases by targeting the Integrated Stress Response (ISR). The company's approach centers on restoring cellular protein synthesis and homeostasis, which are often disrupted in diseases such as Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). By utilizing patient-derived iPSC models, OLAS identifies compounds that can effectively cross the blood-brain barrier and mitigate neurodegeneration. The company is currently advancing its lead candidates through pre-clinical development to address significant unmet needs in the neurology space.